Navigation Links
Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium
Date:12/10/2007

Scientific Presentations Detail Progress with VeraTag(TM) Assays in Breast

Cancer

SOUTH SAN FRANCISCO, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced five posters to be presented at the 30th San Antonio Breast Cancer Symposium taking place in San Antonio, TX, from December 13 - 16, 2007. Following are details for each embargoed session:

-- Friday, December 14th, 2007, 7.00 am - 9.00 am CST

Abstract # 2007: Quantitative measurements of HER2 expression and

HER2:HER2 dimerization identify subgroups of HER2 positive metastatic

breast cancer patients with different probabilities of response to

trastuzumab treatment. (Presenter: W. Huang)

-- Friday, December 14th, 2007, 7.00 am - 9.00 am CST

Abstract # 2011: Development of novel proximity-based immunoassays for

the detection of HER heterodimerization in breast cancer cell line

lysates and formalin-fixed, paraffin-embedded tissue.

(Presenter: L. Eli)

-- Friday, December 14th, 2007, 7.00 am - 9.00 am CST

Abstract # 2012: Characterization of a novel proximity immunoassay for

the quantitative determination of HER2 protein expression and HER2

homodimerization in formalin-fixed, paraffin-embedded breast cancer

tissue. (Presenter: J. Winslow)

-- Saturday, December 15th, 2007, 7.00 am - 9.00 am CST

Abstract # 4108: Profiling HER-family receptor dimerization in HER2

over expressing cells that co-express mutated EGFR receptors.

(Presenter: R. Dua)

-- Saturday, December 15th, 2007, 5.00 pm - 7.00 pm CST

Abstract # 5002: Increased detection of breast cancer markers human

epidermal growth factor receptor dimer and downstream signaling

proteins utilizing the VeraTag technology with dextran modified

antibodies. (Presenter: J. Wallweber)

About HERmark(TM)

HERmark is a propriety diagnostic that accurately quantifies HER2 expression and dimerization in patients with breast cancer. Preliminary data from three cohorts of trastuzumab-treated patients with metastatic breast cancer who were identified as "HER2 positive" by conventional assays suggest that HERMark can identify patients who are likely to respond to Herceptin with greater precision than currently available tests, permitting stratification of patients according to their degree of clinical benefit from the drug. Additional studies of HERmark for breast cancer in both the metastatic and adjuvant settings are in progress.

About VeraTag(TM)

VeraTag is a proximity-based assay technology platform that accurately quantifies proteins and functional protein complexes. This platform provides a researcher or clinician a more thorough understanding of protein-protein interactions or signaling pathway activity allowing for disease characterization at the molecular level. VeraTag is designed to run on standard formalin-fixed paraffin embedded (FFPE) patient samples.

About Monogram

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

VeraTag and HERmark are trademarks of Monogram Biosciences, Inc.

Contacts: Alfred G. Merriweather Jeremiah Hall

Chief Financial Officer Feinstein Kean Healthcare

Tel: 650 624 4576 Tel: 415 677 2700

amerriweather@monogrambio.com jeremiah.hall@fkhealth.com


'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
2. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... , May 9, 2017  Demonstrating its ... board of directors for the Pharmaceutical Research and ... for membership. Biopharmaceutical companies will now have to ... order to be eligible to join PhRMA. ... the board is sending a clear message that ...
(Date:5/8/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., has completed ... a health care service center company based in ... in relationship management programs for leading pharmaceutical manufacturers and ... WRB will join Envoy Health Management, LLC ... manufacturers, biotech firms, and other service companies. Together, WRB ...
(Date:5/4/2017)... 4, 2017  Fortuna Fix Inc. (" Fortuna "), ... first to eliminate the need for embryonic and fetal stem ... neurodegenerative diseases. Fortuna announced today the ... Michael Fehlings , MD, PhD; Father Kevin FitzGerald , ... and Professor James Giordano , PhD. "We ...
Breaking Medicine Technology:
(Date:5/26/2017)... , ... May 26, 2017 , ... After raising nearly ... Top gadget will continue to be available at a discounted crowdfunding price on ... stress wherever they are, I also wanted to bring a fidget toy to the ...
(Date:5/26/2017)... ... May 26, 2017 , ... “When the Stars Lead Home”: a ... creation of published author Laura Weigel Douglas, an avid reader who lives in the ... that sometimes feels like Green Hills Adventure Camp. She couldn’t be more grateful. , ...
(Date:5/26/2017)... ... May 26, 2017 , ... Water damage to the flooring ... School District had left education officials with a number of critical issues to address ... flooring had to be accomplished with little or no disruption to class schedules. Second, ...
(Date:5/24/2017)... San Diego, California (PRWEB) , ... May 24, ... ... patient care through innovative medical image management and interpretation, has received U.S. Food ... technology. , Nucleus.io is a web-based, scalable and secure cloud platform for ...
(Date:5/24/2017)... ... May 24, 2017 , ... Myers Jackson is well known for auctioning homes ... luxury homes anywhere on the planet. The luxury home market is alive and well ... city-scapes. A quick search of “11 Spyglass Hill Auction will enlighten you on the ...
Breaking Medicine News(10 mins):